APEX1 and retinopathy of prematurity: This review explores the redox-regulated transcription factor activity of APE1/Ref-1 and how its effects on inflammation, angiogenesis and other cellular targets make it a potential candidate for therapeutically modulating neovascular eye diseases, such as nvAMD, PDR and ROP, and the vascular leakage of diabetic macular edema (DME).